A novel natural product for the long term management of Osteoporosis, targeted for US FDA approval as OTC (Over The Counter) product. This novel formulation promotes absorption of calcium from gastro-intestinal tract and assimilation by osteophytes (calcinogenic activity). The product is in pre-clinical chemistry and formulation development. The incidence of osteoporosis is approximately 140 million patients in 7 major markets alone, with a prescription market size of more than $8 Billion.
Biologic Response Modifier
This natural dietary supplement protects and restores the body’s immune system and bone marrow to normal levels after suppression by cancer chemotherapy. Chemistry and pre-clinical pharmacology and toxicology have been completed and data has been published in international journals. In animal testing the product shows significant efficacy and safety. The Company plans Phase I and Phase II clinical trials shortly to document efficacy and safety in cancer patients. Currently, the prescription product market size in this category is in excess of $3 Billion.
